Aerosol Drug Delivery

Aerosol Delivery of Biotherapeutics

Inhalation toxicology

 

 

Executive Management


Donovan B. Yeates, Ph.D.
Portrait of Donovan YeatesCEO and CSO, Chairman and Founder of KAER Biotherapeutics
Donovan Yeates is the inventor and developer of SUPRAER™, a system for the generation and delivery of high doses of aerosolized biologics.  He was founder and CEO of an incubator company, BioTechPlex.  BioTechPlex was awarded 11 SBIR Phase I grants and 9 SBIR Phase II grants. Three companies were spawned from BioTechPlex; KAER being the one headed by Dr. Yeates. At the University of Illinois at Chicago, he turned around a university-wide Occupational Health and Safety Center and created a Section of Environmental and Occupational Medicine in the Department of Medicine.  As a Senior Research Career Scientist in the Department of Veterans Affairs, Dr. Yeates directed a respiratory research program.  Dr. Yeates, an emeritus professor with over 90 publications and 5 patents, is an internationally recognized authority in aerosol deposition and respiratory physiology. He is a past president of the Chicago Thoracic Society and served on the Board of Directors of the Illinois Biotechnology Organization (IBIO).  He has a Ph.D. in medical biophysics from the University of Toronto. 

 


Board of Directors


Donovan Yeates, Ph.D. 
Chairman and CEO, KAER Biotherapeutics

Anthony Hickey, Ph.D.
Previously CEO, Cirrus Pharmaceuticals Dr. Hickey has worked in the field of drug delivery to the respiratory tract. He has focused on the development of aqueous and non-aqueous solution / suspension formulations for nebulizer and propellant-driven metered dose inhalers as well as dry powder formulations for delivery to the lungs.He was the recipient of the Young Investigator Award in Pharmaceutics and Pharmaceutical Technology from the American Association of Pharmaceutical Scientists in 1990. He has consulted for the pharmaceutical industry for over a decade. Dr. Hickey was awarded a Ph.D. in Pharmaceutics from the University of Aston in Birmingham, United Kingdom, 1985.

Walter Flicker, M.BioMedEng. Mr. Flicker has over 30 years experience in the life sciences industry, and brings a wealth of experience in the pre-public and public company financial areas. He provides consulting services to start-up companies and venture funds. A major project involved supporting a Los Angeles start-up with the development, clinical trials and FDA clearance of a novel respiratory treatment device, resulting in the sale of the company to Viasys Healthcare (now part of Cardinal Health) for over $20 million.

Previously, Mr. Flicker was the CFO of Respiratory Technology Corporation (Restech). Restech’s novel sensor for non-invasively detecting gastric reflux in the upper airway is gaining increased acceptance in the ENT/pulmonary medicine area, particularly in pediatrics.

Mr. Flicker was a founding executive and officer of ResMed Inc (NYSE: RMD). Mr. Flicker was the initial CFO of ResMed (1989 – 1995) and was responsible for helping take the company from its founding to its public listing on Nasdaq. As CFO Mr. Flicker was responsible for capital raising, financial reporting and financial control and treasury functions. After the Company’s Nasdaq listing, Mr. Flicker held positions as Vice President Corporate Development, Vice President, US Operations and Vice President, Assistant to the Chairman of ResMed. Mr. Flicker holds Bachelor of Engineering (First Class Honors) and Master of Biomedical Engineering degrees from the University of New South Wales, Australia. Mr. Flicker’s strengths are in developing, analyzing and initiating new medical business opportunities for global markets; budgeting and strategic planning; and the management of start-up companies within tight business and financial constraints.

 

 

Copyriight KAER Biotherapeutics Corporation. All Rights Reserved